Eko Analysis Software vs Imbio PHA (4.0.0)
AI Verdict
Choose Eko Analysis Software if…
Choose Eko Analysis Software if you need an FDA-cleared, AI-powered solution for real-time auscultation and early detection of heart murmurs and atrial fibrillation during patient encounters or telehealth visits. This tool is ideal for clinicians seeking to enhance their physical exams with objective heart sound and ECG data, facilitating proactive cardiovascular care and remote patient monitoring.
View Eko Analysis Software →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your workflow involves analyzing CT pulmonary angiogram (CTPA) scans and requires automated, quantitative measurements of cardiac structures to assess right ventricular dilation. This FDA-cleared AI software is best suited for radiologists, cardiologists, and pulmonologists needing rapid, objective insights for diagnosing and risk stratifying pulmonary embolism and hypertension from medical images.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Eko Analysis Software | Imbio PHA (4.0.0) |
|---|---|---|
| Deployment | Unknown | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Analysis SoftwareEko Analysis Software integrates with a mobile app and digital stethoscopes, suggesting a direct, intuitive clinician-facing experience at the point of care. Imbio PHA, while automated and integrated into DICOM workflows, is primarily an image processing software, which often implies a more specialized interface within existing radiology systems.
Clinical Value
TieBoth tools offer significant and FDA-cleared clinical value in their respective domains. Eko focuses on early detection of cardiovascular diseases at the point of care, while Imbio provides critical quantitative data for diagnosis and risk stratification of pulmonary conditions from imaging. Their value propositions address different stages and types of clinical needs.
Pricing & Value
Eko Analysis SoftwareEko Analysis Software offers a transparent freemium model with clear subscription tiers for full features, allowing users to experience basic functionalities before committing. Imbio PHA's 'contact for pricing' approach lacks transparency, making it difficult to assess its value proposition without direct engagement.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA explicitly offers deployment options including 'Enterprise (on-premise)' and integrates seamlessly with 'native DICOM tools and workflows,' which are crucial for large-scale hospital and radiology department IT infrastructure. While Eko is cloud-based and HIPAA compliant, its primary focus on a mobile app for individual clinicians may require more effort for enterprise-wide deployment and integration compared to Imbio's direct imaging workflow integration.
Innovation
TieBoth tools demonstrate significant innovation in their fields. Eko brings AI-powered auscultation to the point of care, transforming a traditional physical exam. Imbio automates complex quantitative analysis of medical images for critical conditions, enhancing diagnostic consistency and speed. Both leverage AI to address important clinical challenges in novel ways.
Support & Docs
Eko Analysis SoftwareEko provides a comprehensive Help Center with user manuals, quick start guides, how-to videos, FAQs, and clinical education resources for both individual and enterprise users. Imbio also offers user manuals and support contact information, but Eko's broader range of readily accessible self-service and educational content suggests a more extensive support ecosystem.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Eko Analysis Software | Imbio PHA (4.0.0) |
|---|---|---|
| Name | Eko Analysis Software | Imbio PHA (4.0.0) |
| Company | Eko Devices | Imbio |
| Primary Data Input | Eko's digital stethoscopes and mobile app (heart sounds and ECGs) | CT pulmonary angiogram (CTPA) scans |
| Primary AI Function | Assists clinicians in early detection of cardiovascular diseases like heart murmurs and atrial fibrillation | Automatically measures cardiac structures from CTPA scans to assess potential right ventricular dilation and aid in diagnosis and risk stratification of pulmonary embolism and hypertension |
| Key Outputs/Reports | Visualization of phonocardiograms (PCG) and ECG tracings, PDF reports | Annotated DICOM images, summary reports in PDF format |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Pulmonology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Eko Analysis Software and Imbio PHA (4.0.0).